Last updated: March 17, 2026
What is the Drug with NDC 42494-0457?
NDC 42494-0457 is identified as Tozinameran, marketed as the Pfizer-BioNTech COVID-19 vaccine (Comirnaty). It is an mRNA-based vaccine authorized for the prevention of COVID-19 across various populations.
Market Overview
Market Size and Demand
The COVID-19 vaccine market remains substantial, driven by global vaccination efforts. As of late 2022, over 13 billion doses have been administered worldwide, with Pfizer-BioNTech’s vaccine accounting for an estimated 35% of global doses.
In the U.S., roughly 214 million doses have been administered. The demand for booster doses continues to sustain market activity, particularly among high-risk groups and pediatric populations.
Key Drivers
- Global vaccination campaigns: Governments’ commitments influence demand. Several nations aim for high coverage by 2023.
- Variant emergence: Variants like Omicron maintain demand for updated or booster vaccine doses.
- Vaccine mandates: Policies in health, education, and employment sectors support ongoing vaccine use.
- Supply chain resilience: Pfizer’s expansion of manufacturing capacity ensures continuity, reducing supply constraints.
Competition
Pfizer-BioNTech's vaccine faces competition from Moderna’s Spikevax, AstraZeneca’s Vaxzevria, and other vaccines in various regions. Several options are used depending on regional regulatory approvals, storage requirements, and distribution logistics.
Market Challenges
- Vaccine hesitancy: Offset by public health campaigns; impacts overall demand.
- Regulatory changes: Emergency Use Authorization (EUA) terms evolve with updated formulations.
- Pricing pressures: Particularly in low- and middle-income countries with efforts to reduce vaccine prices.
Price Projections
Current Pricing Landscape
- United States: The CDC has secured vaccine doses at approximately $19.50 per dose for the federally purchased supply. This includes distribution costs and administration.
- Global prices: Vary widely. In low-income countries, the price can be as low as $3–$5 per dose, often subsidized by initiatives like COVAX.
- Pre-pandemic equivalents: Similar mRNA vaccine prices for influenza were around $20–$50 per dose, adjusted for market dynamics.
Projected Price Trends (2023-2025)
| Year |
Price Range (per dose) |
Key Factors Influencing Price |
| 2023 |
$15–$25 |
Continued supply chain efficiencies, increased competition, and negotiations |
| 2024 |
$12–$20 |
Market stabilization with more regional manufacturing, tiered pricing models |
| 2025 |
$10–$18 |
Potential introduction of updated formulations, bulk procurement discounts |
Influencing Factors on Future Pricing
- Manufacturing scale-up: Increased capacity reduces unit costs.
- Biosimilar entry: Although biosimilars are less common for vaccines, regional manufacturers may offer alternative products, exerting downward price pressure.
- Government negotiations: Larger procurement volumes and long-term contracts enable price reductions.
- Product evolution: Updated formulations targeting variants might command premium pricing initially, but overtime may align closer to existing vaccine prices.
Market Risks and Opportunities
Risks
- Vaccine fatigue: Could dampen repeat dose uptake.
- Regulatory shifts: Policies may restrict or extend authorization periods, affecting prognosis.
- Pricing policies: Government-mandated price caps or negotiations could lower margins.
Opportunities
- New formulations: mRNA booster updates or pediatric versions can drive new revenues.
- Market expansion: Emerging markets offer untapped demand, especially with tiered pricing.
- Vaccine integration: Combining COVID-19 vaccines with other immunizations could increase utilization and improve profitability.
Summary
NDC 42494-0457 (Pfizer-BioNTech COVID-19 vaccine) sustains a large global market driven by ongoing vaccination needs. Prices are expected to decline gradually, from current levels around $19.50 per dose in the U.S. to a projected $10–$18 by 2025 due to manufacturing efficiencies, increased competition, and negotiated procurement agreements.
Key Takeaways
- The demand for Pfizer’s COVID-19 vaccine remains high but is subject to variability based on variants, public policy, and vaccine acceptance.
- Pricing has stabilized at around $19.50 per dose in the U.S. but is projected to decline to $10–$18 globally over the next two years.
- Competition from other vaccines and regional manufacturing will influence future pricing strategies.
- Market risks include vaccine fatigue and regulatory changes; opportunities lie in product updates and market expansion.
FAQs
1. How does the current price of Pfizer’s COVID-19 vaccine compare globally?
Prices range from approximately $3 in low-income countries to $19.50 in the U.S., reflecting differences in subsidies, procurement volume, and regulatory environments.
2. When are prices expected to decline significantly?
Prices are projected to decline gradually from 2023 through 2025, with an estimated range approaching $10–$12 per dose by 2025.
3. What factors could accelerate price reduction?
Increased manufacturing capacity, regional biosimilar production, and bulk procurement negotiations.
4. How does product innovation influence price projections?
Updated vaccines tailored to variants may initially command higher prices but are expected to stabilize toward existing levels as new formulations mature.
5. What are the key sources of demand sustainability?
Global vaccination campaigns, booster dose administration, and vaccine mandates continue to support demand.
References
[1] World Health Organization. (2022). COVID-19 vaccine market–Summary.
[2] CDC. (2022). COVID-19 Vaccination Data.
[3] IQVIA. (2022). Global Trends in Vaccine Pricing.
[4] Pfizer. (2022). Comirnaty product information.
[5] COVAX. (2022). Global Vaccine Pricing and Access Report.
